Skip to main content
Premium Trial:

Request an Annual Quote

Cota Raises $40M in Series C Round

NEW YORK (GenomeWeb) – Healthcare data analytics company Cota announced today that it has closed a $40 million Series C round of financing.

The round was led by Iqvia with participation from EW Healthcare Partners and Memorial Sloan Kettering Cancer Center, as well as existing investors Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health, and Atoc Holdings. In connection with the transaction, Iqvia has received a seat on Cota's board.

The company said it would use the funding to advance its Cota Nodal Address classification system — which creates patient cohorts by categorizing patient-specific medical histories, information on their diseases, and planned therapies — and to scale up its other real-world evidence and analytics platforms geared toward healthcare providers, payors, and life science companies.

Earlier this year, Cota was selected to help develop precision medicine and research programs at the Miami Cancer Institute. And in late 2017, the firm partnered with Memorial Sloan Kettering Cancer Center to build clinical and genomic data sets for personalized medicine. In 2016, Cota began collaborating with Guardant Health to study barriers to genomic profiling in lung cancer patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.